Select Language
CD4
CD4 Overview
| English Name | T-cell surface antigen CD4 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 25 | Target Synonym | CD4mut，CD4 Antigens，T-cell surface antigen T4/Leu-3，T-cell surface glycoprotein CD4，CD4，CD4 Molecule，CD4 Antigen (P55)，CD4 Receptor，CD4 Antigen |
| Highest Development Stage | Approved | ||
| English Name | T-cell surface antigen CD4 |
| Target Synonym | CD4mut，CD4 Antigens，T-cell surface antigen T4/Leu-3，T-cell surface glycoprotein CD4，CD4，CD4 Molecule，CD4 Antigen (P55)，CD4 Receptor，CD4 Antigen |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 25 |
| Highest Development Stage | Approved |
CD4 Product List
- Product Category
Protein (15)Antibody (2)Cell Grade Beads (1)
- Product Status
Launched (18)
- Species
Human (13)Rhesus macaque (3)Rabbit (1)Mouse (1)
- Tag
Fc Tag (3)His Tag (9)Fc Tag & Avi Tag (1)His Tag & Avi Tag (2)- (3)
- Conjugate
Unconjugated (5)Biotin-labeled (3)FITC Labeled (2)PE Labeled (2)APC Labeled (1)PE-CY7 Labeled (1)AF488 Labeled (2)AF647 Labeled (1)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT CD4-H82E8 |  Human | HEK293 | Biotinylated Human CD4 Protein, His,Avitag™ (MALS verified) |  |  |  |  Add to Cart |
HOT CD4-HA2H9 | Human | HEK293 | APC-Labeled Human CD4 Protein, His TagStar Staining |  | Add to Cart | ||
HOT CD4-HF255 | Human | HEK293 | FITC-Labeled Human CD4 Protein, Fc Tag |  | | | Add to Cart |
HOT CD4-HP2E3 | Human | HEK293 | PE-Labeled Human CD4 Protein, His Tag (Site-specific conjugation) |  |  | Add to Cart | |
HOT LE3-H5228 | Human | HEK293 | Human CD4 / LEU3 Protein, His Tag (MALS verified) |  | | | Add to Cart |
CD4-H5259 | Human | HEK293 | Human CD4 Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
CD4-H82F3 | Human | HEK293 | Biotinylated Human CD4 Protein, Fc,Avitag™ (MALS verified) |  | | | Add to Cart |
CD4-HA225 | Human | HEK293 | Alexa Fluor™ 488-Labeled Human CD4 Protein, His Tag |  | | Add to Cart | |
CD4-HA2H7 | Human | HEK293 | Alexa Fluor™ 488-Labeled Human CD4 Protein, His TagStar Staining | | Add to Cart | ||
CD4-HA2H8 | Human | HEK293 | Alexa Fluor™ 647-Labeled Human CD4 Protein, His TagStar Staining | | Add to Cart |
Total: 18
- 1
- 2
CD4 Background
T-cell surface glycoprotein CD4 is also known as T-cell surface antigen T4/Leu-3. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is accessory protein for MHC class-II antigen/T-cell receptor interaction. CD4 induces the aggregation of lipid rafts. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.
CD4 Synonyms
CD4,CD4mut,LEU3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Semzuvolimab | dB4; UB-421; mAb-B4 | Phase 3 Clinical | United Biomedical Inc | HIV Infections | Details |
| ITV 1(Nonindustrial source) | ITV-1 | Phase 3 Clinical | Immunotech Laboratories, Synexa Life Sciences | HIV Infections | Details |
| RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
| VRC-01-LS | VRC-HIVMAB-080-00-AB; VRC-01-LS | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| VRC-07-523 | VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc | Acquired Immunodeficiency Syndrome; HIV Infections; Sexually Transmitted Diseases, Viral | Details |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck | Details |
| Tregalizumab | hB-F5; BT-061 | Phase 2 Clinical | Biotest Pharma Gmbh | Arthritis, Rheumatoid; Asthma; Drug Hypersensitivity; Psoriasis | Details |
| Lotivibart | VH-3810109; GSK-3810109-A; VH-109; N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB; GSK-3810109 | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| MR-001 | MR001; MR-001 | Phase 2 Clinical | Shenzhen Maijiarui Biotechnology Co Ltd | Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IMCY-0141 | IMCY-0141 | Phase 2 Clinical | Imcyse Sa | Multiple Sclerosis, Relapsing-Remitting | Details |
| Autologous Regulatory Т-cell Therapy | Phase 2 Clinical | Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus | Scleroderma, Systemic | Details | |
| TMB-365 | TMB-365 | Phase 2 Clinical | Taimed Biologics Inc | HIV Infections | Details |
| CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) | CD4CAR (Icell Gene) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd, Stony Brook University School Of Medicine, University Of Louisville | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, T-Cell; Lymphoma, T-Cell | Details |
| T-allo-10 | T-allo-10 | Phase 1 Clinical | Stanford University | Graft vs Host Disease; Hematologic Diseases; Hodgkin Disease; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD4 CAR T-cell therapy (University of Pennsylvania) | CAR-C34ZFN | Phase 1 Clinical | University Of Pennsylvania | HIV Infections | Details |
| 10E8.4/iMab (Aaron Diamond AIDS Research Center) | TMB-370 | Phase 1 Clinical | Aaron Diamond Aids Research Center For The City Of New York, Inc | HIV Infections | Details |
| CD4CAR | ICG-122; CD4CAR | Phase 1 Clinical | iCell Gene Therapeutics LLC | Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Mycosis Fungoides; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| MazF gene therapy (Takara Bio) | Phase 1 Clinical | Takara Bio Inc | HIV Infections | Details | |
| CALRLong36 peptide (Herlev Hospital) | Phase 1 Clinical | Herlev Hospital | Myeloproliferative Disorders | Details | |
| VRC-HIVMAB060-00-AB | VRC-HIVMAB060-00-AB; VRC01 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details |
| VRC-HIVMAB0115-00-AB | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| LM-49 | Phase 1 Clinical | Shanxi Medical University, Shanxi University Of Traditional Chinese Medicine | Diabetic Nephropathies | Details | |
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| LB-1901 | LB1901; LB-1901 | Phase 1 Clinical | Leukemia, T-Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral | Details | |
| IT-1208 (Kyowa Hakko Kirin) | IT-1208 | Phase 1 Clinical | Kyowa Hakko Kirin Co Ltd | Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ibalizumab | Hu5A8; TMB-355; TNX-355; 5AB | Approved | Biogen Inc | 特罗格佐, Trogarzo | United States | HIV Infections | Theratechnologies Inc | 2018-03-06 | HIV Infections | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: